36 results on '"Kukin ML"'
Search Results
2. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial.
- Author
-
Colucci WS, Kolias TJ, Adams KF, Armstrong WF, Ghali JK, Gottlieb SS, Greenberg B, Klibaner MI, Kukin ML, Sugg JE, REVERT Study Group, Colucci, Wilson S, Kolias, Theodore J, Adams, Kirkwood F, Armstrong, William F, Ghali, Jalal K, Gottlieb, Stephen S, Greenberg, Barry, Klibaner, Michael I, and Kukin, Marrick L
- Published
- 2007
3. Implantable cardioverter-defibrillators.
- Author
-
Kukin ML
- Published
- 2009
- Full Text
- View/download PDF
4. Public perception of heart failure on twitter: A sentiment analysis.
- Author
-
Krittanawong C, Kitai T, Rodriguez M, Kaplin S, Bozkurt B, Kukin ML, and Tang W
- Subjects
- Data Mining, Heart Failure diagnosis, Heart Failure epidemiology, Heart Failure physiopathology, Humans, Sentiment Analysis, Health Knowledge, Attitudes, Practice, Healthy Lifestyle, Heart Failure prevention & control, Primary Prevention, Public Opinion, Risk Reduction Behavior, Social Media
- Abstract
Competing Interests: Declaration of Competing Interest Dr Krittanawong discloses the following relationships: Member of the American College of Cardiology Solution Set Oversight Committee, the American Heart Association Committee of the Council on Genomic and Precision Medicine, and the American College of Cardiology/American Heart Association Task Force on Performance Measures, The Lancet Digital Health (Advisory Board), European Heart Journal Digital Health (Editorial board), Journal of the American Heart Association (Editorial Board), Journal of the American College of Cardiology: Asia (Section Editor), and The Journal of Scientific Innovation in Medicine (Associate Editor)
- Published
- 2021
- Full Text
- View/download PDF
5. Current Management and Future Directions of Heart Failure With Preserved Ejection Fraction: a Contemporary Review.
- Author
-
Krittanawong C and Kukin ML
- Abstract
Heart failure with preserved ejection fraction (HFpEF), a complex and debilitating syndrome, is commonly seen in elderly populations. Exacerbation of HFpEF is among the most common reasons for hospital admission in the USA. The high rate of morbidity and mortality from this condition underscores the fact that HFpEF is heterogeneous, complex, and poorly characterized. Randomized, controlled trials have been very successful at identifying treatments for HF with reduced ejection fraction (HFrEF), but effective treatment options for HFpEF are lacking. Here, we discuss (1) the pathophysiology of HFpEF, (2) a standardized diagnostic and therapeutic approach, (3) a comparison of the management of recent guidelines, and (4) challenges and future directions for HFpEF management. The authors believe that it is important to identify new subtypes of HFpEF to better classify genotypes and phenotypes of HFpEF and to develop novel targeted therapies. It is our hypothesis that big data analytics will shine new light on unique HFpEF phenotypes that better respond to treatment modalities.
- Published
- 2018
- Full Text
- View/download PDF
6. Farewell to PCVD.
- Author
-
Greenberg H, Kukin ML, and Messerli FH
- Subjects
- Cardiology, Humans, Societies, Medical, United States, Cardiovascular Diseases, Periodicals as Topic
- Published
- 2013
- Full Text
- View/download PDF
7. Malnutrition as assessed by nutritional risk index is associated with worse outcome in patients admitted with acute decompensated heart failure: an ACAP-HF data analysis.
- Author
-
Aziz EF, Javed F, Pratap B, Musat D, Nader A, Pulimi S, Alivar CL, Herzog E, and Kukin ML
- Abstract
Malnutrition is common at hospital admission and tends to worsen during hospitalization. This controlled population study aimed to determine if serum albumin or moderate and severe nutritional depletion by Nutritional Risk Index (NRI) at hospital admission are associated with increased length of hospital stay (LOS) in patients admitted with acute decompensated heart failure (ADHF). Serum albumin levels and lymphocyte counts were retrospectively determined at hospital admission in 1740 consecutive patients admitted with primary and secondary diagnosis of ADHF. The Nutrition Risk Score (NRI) developed originally in AIDS and cancer populations was derived from the serum albumin concentration and the ratio of actual to usual weight, as follows: NRI = (1.519 × serum albumin, g/dL) + {41.7 × present weight (kg)/ideal body weight(kg)}. Patients were classified into four groups as no, mild, moderate or severe risk by NRI. Multiple logistic regressions were used to determine the association between nutritional risk category and LOS.Three hundred and eighty-one patients (34%) were at moderate or severe nutritional risk by NRI score. This cohort had lower BMI (24 ± 5.6 kg/m(2)), albumin (2.8±0.5 g/dL), mean NRI (73.5±9) and lower eGFR (50±33 mL/min per 1.73 m(2)). NRI for this cohort, adjusted for age, was associated with LOS of 10.1 days. Using the Multiple Logistic regression module, NRI was the strongest predictor for LOS (OR 1.7, 95% CI: 1.58-1.9; P=0.005), followed by TIMI Risk Score [TRS] (OR 1.33, 95% CI: 1.03-1.71; P=0.02) and the presence of coronary artery disease (OR 2.29, 95%CI: 1.03-5.1; P=0.04). Moderate and severe NRI score was associated with higher readmission and death rates as compared to the other two groups.Nutritional depletion as assessed by Nutritional Risk Index is associated with worse outcome in patients admitted with ADHF. Therefore; we recommend adding NRI to further risk stratify these patients.
- Published
- 2011
- Full Text
- View/download PDF
8. The most important issue: use beta blockers.
- Author
-
Kukin ML
- Subjects
- Adrenergic alpha-Antagonists therapeutic use, Clinical Trials as Topic, Humans, Adrenergic beta-Antagonists therapeutic use, Heart Failure drug therapy
- Published
- 2003
- Full Text
- View/download PDF
9. Beta-blockers in chronic heart failure: considerations for selecting an agent.
- Author
-
Kukin ML
- Subjects
- Adrenergic beta-Antagonists adverse effects, Aged, Aged, 80 and over, Chronic Disease, Controlled Clinical Trials as Topic, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Heart Failure diagnosis, Humans, Long-Term Care, Male, Middle Aged, Prognosis, Risk Assessment, Severity of Illness Index, Survival Analysis, Treatment Outcome, Adrenergic beta-Antagonists administration & dosage, Heart Failure drug therapy, Heart Failure mortality
- Abstract
Patients with chronic heart failure have increased sympathetic nervous system activity that contributes to deterioration of cardiovascular function over time. Long-term beta-blocker therapy prevents such deterioration through inhibition of this neurohormonal pathway. The impressive survival data collected from several large studies have made beta-blockers a component of standard therapy for New York Heart Association class II to III heart failure. Although there are differences in the pharmacological properties of the beta-blockers shown to improve morbidity and mortality in heart failure, there is little evidence to suggest that such properties constitute any major advantages in clinical outcome. Carvedilol and extended-release metoprolol succinate are 2 beta-blockers currently approved in the United States for the treatment of patients with heart failure. Both agents have shown similar risk reductions in overall and cause-specific mortality; however, no outcome data from a comparative trial are available to support the use of one agent over the other. Regardless of the agent chosen, appropriate dosing and titration of beta-blockers are essential for successful therapy.
- Published
- 2002
- Full Text
- View/download PDF
10. Are all beta blockers the same for heart failure?
- Author
-
Kukin ML IV
- Abstract
Based on impressive morbidity and mortality data using beta blockers in heart failure, this therapy has now become part of the standard of care for patients with New York Heart Association II/III symptoms. The question remains whether there are clinically relevant differences between the beta blockers that have shown beneficial effects. This review summarizes the major mortality trials, and examines the smaller comparative trials of second and third generation beta blockers.
- Published
- 2000
- Full Text
- View/download PDF
11. Beta-blockers and spironolactone in heart failure.
- Author
-
Kukin ML
- Subjects
- Carbazoles therapeutic use, Carvedilol, Humans, Metoprolol therapeutic use, Propanolamines therapeutic use, Randomized Controlled Trials as Topic, Treatment Outcome, Adrenergic beta-Antagonists therapeutic use, Heart Failure drug therapy, Mineralocorticoid Receptor Antagonists therapeutic use, Spironolactone therapeutic use
- Abstract
Neurohormonal antagonism is now recognized as an essential treatment modality for heart failure. As a prime example, the benefits of blocking the renin-angiotensin system with angiotensin converting enzyme inhibitors are clearly established for all four New York Heart Association classes. In this clinical trials review, we discuss two other therapies with neurohormonal targets: beta-blockers and the sympathetic nervous system, and the aldosterone antagonist spironolactone.
- Published
- 2000
- Full Text
- View/download PDF
12. Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction.
- Author
-
Udelson JE, DeAbate CA, Berk M, Neuberg G, Packer M, Vijay NK, Gorwitt J, Smith WB, Kukin ML, LeJemtel T, Levine TB, and Konstam MA
- Subjects
- Aged, Amlodipine adverse effects, Calcium Channel Blockers adverse effects, Double-Blind Method, Exercise Test, Female, Heart Failure etiology, Hemodynamics drug effects, Humans, Male, Middle Aged, Severity of Illness Index, Treatment Outcome, Ventricular Dysfunction, Left complications, Ventricular Function, Left drug effects, Walking, Amlodipine therapeutic use, Calcium Channel Blockers therapeutic use, Exercise Tolerance drug effects, Heart Failure drug therapy, Quality of Life, Ventricular Dysfunction, Left drug therapy
- Abstract
Background: A preliminary study suggested that the long-acting late-generation calcium-channel blocker amlodipine has favorable effects on exercise tolerance and is safe to use in heart failure, in contrast to earlier generation agents. The goal of 2 multicenter studies was to assess the effect of adjunctive therapy with amlodipine in addition to standard therapy on exercise capacity, quality of life, left ventricular function, and safety parameters in patients with heart failure and left ventricular systolic dysfunction., Methods: Two large multicenter trials examining the effects of amlodipine on these parameters over a 12-week period of therapy were undertaken in patients with mild to moderate heart failure and left ventricular systolic dysfunction. A total of 437 patients with stable heart failure were studied in a randomized, double-blind, placebo-controlled prospective design., Results: Amlodipine at a dose of 10 mg/day in addition to standard therapy in such patients was associated with no significant difference in change in exercise tolerance on a Naughton protocol compared with placebo in each trial. Among all patients taking amlodipine, exercise time increased 53 +/- 9 (SE) seconds; exercise time for those taking placebo increased 66 +/- 9 seconds (P = not significant). There were no significant differences in changes of quality of life parameters between amlodipine- and placebo-treated patients, and there were no significant differences in symptom scores or New York Heart Association classification between groups. Left ventricular function (measured as ejection fraction) improved 3. 4% +/- 0.5% in amlodipine-treated patients and 1.5% +/- 0.5% in placebo-treated patients (P =.007). There was no statistically significant excess of important adverse events (episodes of worsening heart failure in 10% amlodipine-treated vs 6.3% of placebo-treated patients) or differences in need for changes in background medication between groups., Conclusions: The addition of 10 mg of amlodipine per day to standard therapy in patients with heart failure is associated with no significant improvement in exercise time compared with placebo therapy over a 12-week period, and there was no increased incidence of adverse events. These data suggest that the addition of amlodipine to standard therapy in heart failure will not result in additional efficacy per se beyond standard therapy.
- Published
- 2000
- Full Text
- View/download PDF
13. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators.
- Author
-
Teerlink JR, Jalaluddin M, Anderson S, Kukin ML, Eichhorn EJ, Francis G, Packer M, and Massie BM
- Subjects
- Arrhythmias, Cardiac physiopathology, Cause of Death, Electrocardiography, Ambulatory, Female, Heart Failure mortality, Heart Ventricles, Humans, Male, Middle Aged, Multivariate Analysis, Predictive Value of Tests, Prognosis, Regression Analysis, Risk Factors, Systole, Arrhythmias, Cardiac complications, Cardiotonic Agents therapeutic use, Death, Sudden, Cardiac epidemiology, Heart Failure complications, Heart Failure drug therapy, Milrinone therapeutic use
- Abstract
Background: Ventricular arrhythmias are a frequent finding in congestive heart failure (CHF) patients and a cause of concern for physicians caring for them. Previous studies have reached conflicting conclusions regarding the importance of ventricular arrhythmias as predictors of sudden death in patients with CHF. This study examined the independent predictive value of ventricular arrhythmias for sudden death and all-cause mortality in PROMISE (Prospective Randomized Milrinone Survival Evaluation)., Methods and Results: Ventricular arrhythmias were analyzed and quantified by use of prespecified criteria on baseline ambulatory ECGs from 1080 patients with New York Heart Association (NYHA) class III/IV symptoms and a left ventricular ejection fraction =35% enrolled in PROMISE. The relationship of ventricular arrhythmias and other clinical parameters to overall mortality and sudden death classified by an independent, blinded mortality committee was determined. There were 290 deaths, of which 139 were classified as sudden. Of the several measures of ventricular ectopy that were univariate predictors, the frequency of nonsustained ventricular tachycardia (NSVT) was the most powerful predictor and remained a significant independent predictor when included with other clinical variables in multivariate models of both sudden death mortality and non-sudden death mortality. However, multiple logistic analysis with models including the clinical variables with and without the NSVT variable demonstrated that the frequency of NSVT did not add significant information beyond the clinical variables., Conclusions: This study demonstrates that ventricular arrhythmias do not specifically predict sudden death in patients with moderate-to-severe heart failure. Thus, the finding of asymptomatic NSVT on ambulatory ECG does not identify specific candidates for antiarrhythmic or device therapy.
- Published
- 2000
- Full Text
- View/download PDF
14. Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure.
- Author
-
Kukin ML, Mannino MM, Freudenberger RS, Kalman J, Buchholz-Varley C, and Ocampo O
- Subjects
- Administration, Oral, Adrenergic beta-Antagonists adverse effects, Adult, Aged, Dose-Response Relationship, Drug, Drug Administration Schedule, Exercise Test, Female, Heart Failure physiopathology, Hemodynamics physiology, Humans, Long-Term Care, Male, Metoprolol adverse effects, Middle Aged, Treatment Outcome, Adrenergic beta-Antagonists administration & dosage, Heart Failure drug therapy, Hemodynamics drug effects, Metoprolol administration & dosage, Metoprolol analogs & derivatives
- Abstract
Objectives: To compare the hemodynamic effects of twice daily metoprolol tartrate (MT) and once daily metoprolol succinate (MS) in congestive heart failure patients., Background: Adverse hemodynamic effects with MT demonstrated during initiation persist with drug readministration during chronic therapy., Methods: Patients were randomly assigned to 6.25 mg MT or 25 mg MS orally and the dose was gradually increased to a target of 50 mg twice a day or 100 mg once a day, respectively. Hemodynamic measurements were obtained at baseline and after three months of therapy--both before and after drug readministration., Results: Long term metoprolol therapy produced significant functional, exercise and hemodynamic benefits with no difference in response between either metoprolol preparation in the 27 patients (MT [14], MS [13]). When full dose metoprolol was readministered during chronic therapy, there were parallel adverse hemodynamic effects in both drug groups. Cardiac index decreased by 0.6 liters/min/m2 (p < 0.0001) with MT and by 0.5 liters/min/m2 (p < 0.0001) with MS. Systematic vascular resistance increased by 253 dyne-sec-cm(-5) (p < 0.001) with MT and by 267 dyne-sec-cm(-5) (p < 0.0005) with MS. Stroke volume index decreased by 7.0 ml/m2 (p < 0.0005) with MT and by 6.5 ml/m2 (p < 0.0001) with MS, while SWI decreased by 6.2 g-m/m2 (p < 0.0005) with MT and by 6.0 g-m/m2 (p < 0.001) with MS., Conclusion: Metoprolol tartrate and MS produce similar hemodynamic and clinical effects acutely and chronically despite the fourfold greater starting dose of MS used in this study. A more rapid initiation with readily available starting doses of MS may offer distinct advantages compared with MT in treating chronic heart failure patients with beta-adrenergic blocking agents.
- Published
- 2000
- Full Text
- View/download PDF
15. Short-term and long-term hemodynamic and clinical effects of metoprolol alone and combined with amlodipine in patients with chronic heart failure.
- Author
-
Kukin ML, Freudenberger RS, Mannino MM, Kalman J, Steinmetz M, Buchholz-Varley C, and Ocampo ON
- Subjects
- Adrenergic beta-Antagonists therapeutic use, Adult, Amlodipine therapeutic use, Calcium Channel Blockers therapeutic use, Drug Therapy, Combination, Female, Heart Failure physiopathology, Humans, Male, Metoprolol therapeutic use, Middle Aged, Prospective Studies, Time Factors, Treatment Outcome, Vascular Resistance drug effects, Adrenergic beta-Antagonists pharmacology, Amlodipine pharmacology, Calcium Channel Blockers pharmacology, Heart Failure drug therapy, Hemodynamics drug effects, Metoprolol pharmacology
- Abstract
Background: Initiation of beta-blocker therapy is often limited by worsening congestive heart failure, which may manifest as worsening hemodynamics. Deleterious hemodynamic effects might be mitigated with the vasodilation of combined calcium channel/beta-blocker therapy., Methods and Results: This prospective, randomized study assessed the safety and efficacy of metoprolol alone or combined with amlodipine on hemodynamic parameters at baseline, 2 hours after the first dose of study medication, and after 12 weeks of therapy in patients receiving background triple therapy for mild to severe heart failure. Functional, exercise, and hormonal status were assessed at baseline and end of study. Twenty-nine patients (mean age 50 +/- 12.1 years) were enrolled; 21 completed 12 weeks of treatment. Mean ejection fraction at baseline was 13.4% +/- 5.7%; 79% of patients had heart failure classified as New York Heart Association class III, and 66% had heart failure of idiopathic origin. Heart rate and blood pressure did not change with short-term therapy in either group. The first dose of both regimens produced significant increases in systemic vascular resistance and significant decreases in cardiac output and index and stroke volume and stroke work indexes; combination therapy acutely yielded small but statistically significant increases in pulmonary artery, pulmonary capillary wedge, and right atrial pressures. Long-term therapy with both regimens produced significant decreases in heart rate, systemic vascular resistance, and pulmonary capillary wedge pressure and significant increases in cardiac output and index and stroke volume and stroke work indexes. Combination therapy produced significant long-term decreases in blood pressure., Conclusions: There was no further measurable benefit with the addition of amlodipine to metoprolol compared with the effects of metoprolol alone. Therapy with metoprolol alone and the combination of metoprolol and amlodipine was well tolerated in patients with mild to severe heart failure, as evidenced by a lack of adverse effects on hemodynamic parameters over the short term and clinical and hemodynamic improvement with long-term treatment.
- Published
- 1999
- Full Text
- View/download PDF
16. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure.
- Author
-
Kukin ML, Kalman J, Charney RH, Levy DK, Buchholz-Varley C, Ocampo ON, and Eng C
- Subjects
- Adult, Aged, Cardiac Output, Low metabolism, Cardiac Output, Low physiopathology, Carvedilol, Chronic Disease, Female, Humans, Male, Middle Aged, Prospective Studies, Thiobarbituric Acid Reactive Substances metabolism, Adrenergic beta-Antagonists therapeutic use, Carbazoles therapeutic use, Cardiac Output, Low drug therapy, Exercise, Metoprolol therapeutic use, Oxidative Stress drug effects, Propanolamines therapeutic use, Stroke Volume drug effects
- Abstract
Background: With beta-blocker use becoming more prevalent in treating chronic heart failure (CHF), the choice of drugs raises important theoretical and practical questions. Although the second-generation compound metoprolol is beta1-selective, the third-generation compound carvedilol is beta-nonselective, with ancillary pharmacological properties including alpha-blockade and antioxidant effects. A prospective comparison of these 2 agents can address the issue of optimal adrenergic blockade in selecting agents for therapy in CHF., Methods and Results: Sixty-seven patients with symptomatic stable heart failure were randomly assigned to receive either carvedilol or metoprolol in addition to standard therapy for CHF. Measured variables included symptoms, exercise, ejection fraction, and thiobarbituric acid-reactive substances (TBARS) as an indirect marker of free radical activity. Metoprolol and carvedilol were well tolerated, and both patient groups showed beneficial effects of beta-blocker therapy in each of the measured parameters, with no between-group differences. Ejection fraction increased over 6 months from 18+/-6.3% to 23+/-8.7% (P<0.005) with metoprolol and from 19+/-8.5% to 25+/-9.9% (P<0.0005) with carvedilol (P=NS between groups). With metoprolol, TBARS values decreased from 4.7+/-0.9 nmol/mL at baseline to 4.2+/-1.5 nmol/mL at month 4 to 3.9+/-1.0 nmol/mL at month 6 (P<0.0001). With carvedilol, there was a parallel decline from 4.7+/-1.4 to 4.2+/-1.3 to 4.1+/-1.2 nmol/mL over the same time frame (P<0.025), with no between-group difference in these changes., Conclusions: Carvedilol and metoprolol showed parallel beneficial effects in the measured parameters over 6 months, with no relevant between-group differences in this heart failure population.
- Published
- 1999
- Full Text
- View/download PDF
17. Beta blockade in congestive heart failure: persistent adverse haemodynamic effects during chronic treatment with subsequent doses.
- Author
-
Kukin ML, Kalman J, Mannino MM, Buchholz-Varley C, and Ocampo O
- Subjects
- Adrenergic beta-Antagonists therapeutic use, Adult, Aged, Analysis of Variance, Female, Heart Failure physiopathology, Heart Rate drug effects, Humans, Male, Metoprolol therapeutic use, Middle Aged, Pulmonary Wedge Pressure drug effects, Stroke Volume drug effects, Time Factors, Vascular Resistance drug effects, Adrenergic beta-Antagonists adverse effects, Heart Failure drug therapy, Hemodynamics drug effects, Metoprolol adverse effects
- Abstract
Objective: To determine whether the acute adverse haemodynamic effects of beta blockade in patients with congestive heart failure persist during chronic treatment., Design: Sequential haemodynamic evaluation of heart failure patients at baseline and after three months of continuous treatment with the beta 1 selective antagonist metoprolol., Setting: Cardiac care unit in university hospital., Patients: 26 patients with moderate to severe congestive heart failure (New York Heart Association grade II to IV) and background treatment with digoxin, diuretics, and angiotensin converting enzyme inhibitors, and with a left ventricular ejection fraction < 25%., Methods: Baseline variables included a six minute walk, maximum oxygen consumption, and right heart catheterisation. All patients received metoprolol 6.25 mg orally twice daily initially and the dose was gradually increased to a target of 50 mg twice daily. Haemodynamic measurements were repeated after three months of treatment, both before (trough) and after drug readministration., Results: Long term metoprolol had functional, exercise, and haemodynamic benefits. It produced decreases in heart rate, pulmonary capillary wedge pressure, and systemic vascular resistance, and increases in cardiac index, stroke volume index, and stroke work index. However, when full dose metoprolol was readministered during chronic treatment, there was a reduction in cardiac index (from 2.8 (SD 0.46) to 2.3 (0.38) l/min/m2, p << 0.001) and stroke work index (from 31.4 (11.1) to 26.6 (10.0) g.m/m2, p < 0.001) and an increase in systemic vascular resistance (from 943 (192) to 1160 (219) dyn.s.cm-5, p << 0.001)., Conclusions: Adverse haemodynamic effects of beta blockers in heart failure persist during chronic treatment, as shown by worsening haemodynamic indices with subsequent doses.
- Published
- 1997
- Full Text
- View/download PDF
18. Noninvasive measurement of cardiac output by an acetylene uptake technique and simultaneous comparison with thermodilution in ICU patients.
- Author
-
Sadeh JS, Miller A, and Kukin ML
- Subjects
- Absorption, Administration, Inhalation, Adult, Aged, Capillaries physiology, Cardiomyopathies blood, Cardiomyopathies physiopathology, Coronary Artery Bypass, Female, Heart Transplantation physiology, Humans, Liver Transplantation physiology, Male, Middle Aged, Monitoring, Ambulatory, Pulmonary Alveoli metabolism, Pulmonary Circulation, Respiration, Tricuspid Valve Insufficiency blood, Tricuspid Valve Insufficiency physiopathology, Vascular Surgical Procedures, Acetylene administration & dosage, Acetylene blood, Acetylene pharmacokinetics, Cardiac Output, Critical Care, Thermodilution
- Abstract
A simple, accurate, and noninvasive method of cardiac output measurement can be an extremely useful tool for the clinician and researcher. This study used the acetylene gas uptake technique to measure the absorption of acetylene into the pulmonary circulation during a constant exhalation, which is proportional to the pulmonary capillary blood flow and to the cardiac output, assuming no anatomic shunts. We compared cardiac output measured simultaneously by this and by the standard thermodilution (TD) technique in 21 patients in the ICU with a variety of medical and surgical conditions and a wide range of cardiac outputs. We also compared the two techniques in 19 ambulatory patients with a 2-h interval between the invasive and noninvasive test to assess variability over time. The two tests had an excellent correlation when done simultaneously with a correlation coefficient of 0.89 (p < 0.001). With a 2-h interval between the two tests, the correlation coefficient was 0.66 (p = 0.0018). Nine patients in the simultaneous group had cardiomyopathy. When they were excluded, the correlation coefficient increased to 0.96. Most of these patients had documented tricuspid regurgitation (TR), which may underlie the greater difference between acetylene uptake and TD values, with consistently higher TD values in these patients. This study confirms the correlation between the acetylene uptake and the standard invasive TD techniques in sick patients with various medical and surgical conditions and a wide range of cardiac outputs. Furthermore, we believe this would be a more accurate method for measuring cardiac output in patients with cardiomyopathy and TR because it is based only on pulmonary capillary blood flow.
- Published
- 1997
- Full Text
- View/download PDF
19. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.
- Author
-
Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, and Shusterman NH
- Subjects
- Adrenergic beta-Antagonists adverse effects, Aged, Carbazoles adverse effects, Cardiac Output, Low mortality, Cardiac Output, Low physiopathology, Carvedilol, Double-Blind Method, Female, Humans, Male, Middle Aged, Morbidity, Placebos, Propanolamines adverse effects, Risk Factors, Severity of Illness Index, Stroke Volume drug effects, Treatment Outcome, Adrenergic beta-Antagonists therapeutic use, Carbazoles therapeutic use, Cardiac Output, Low drug therapy, Propanolamines therapeutic use
- Abstract
Background: Carvedilol has improved the symptomatic status of patients with moderate to severe heart failure in single-center studies, but its clinical effects have not been evaluated in large, multicenter trials., Methods and Results: We enrolled 278 patients with moderate to severe heart failure (6-minute walk distance, 150 to 450 m) and a left ventricular ejection fraction < or = 0.35 at 31 centers. After an open-label, run-in period, each patient was randomly assigned (double-blind) to either placebo (n = 145) or carvedilol (n = 133; target dose, 25 to 50 mg BID) for 6 months, while background therapy with digoxin, diuretics, and an ACE inhibitor remained constant. Compared with placebo, patients in the carvedilol group had a greater frequency of symptomatic improvement and lower risk of clinical deterioration, as evaluated by changes in the NYHA functional class (P = .014) or by a global assessment of progress judged either by the patient (P = .002) or by the physician (P < .001). In addition, treatment with carvedilol was associated with a significant increase in ejection fraction (P < .001) and a significant decrease in the combined risk of morbidity and mortality (P = .029). In contrast, carvedilol therapy had little effect on indirect measures of patient benefit, including changes in exercise tolerance or quality-of-life scores. The effects of the drug were similar in patients with ischemic heart disease or idiopathic dilated cardiomyopathy as the cause of heart failure., Conclusions: These findings indicate that, in addition to its favorable effects on survival, carvedilol produces important clinical benefits in patients with moderate to severe heart failure treated with digoxin, diuretics, and an ACE inhibitor.
- Published
- 1996
- Full Text
- View/download PDF
20. Combined alpha-beta blockade (doxazosin plus metoprolol) compared with beta blockade alone in chronic congestive heart failure.
- Author
-
Kukin ML, Kalman J, Mannino M, Freudenberger R, Buchholz C, and Ocampo O
- Subjects
- Adult, Aged, Chronic Disease, Drug Therapy, Combination, Female, Heart Failure physiopathology, Humans, Male, Middle Aged, Treatment Outcome, Adrenergic alpha-Antagonists therapeutic use, Adrenergic beta-Antagonists therapeutic use, Doxazosin therapeutic use, Heart Failure drug therapy, Hemodynamics drug effects, Metoprolol therapeutic use
- Abstract
There has been growing evidence for the benefits of beta blockers, but alpha blockers have not shown sustained benefits in chronic congestive heart failure (CHF). Thirty patients with moderate to severe CHF (New York Heart Association class II to IV) were sequentially assigned to receive metoprolol 6.25 mg with the alpha-1 antagonist doxazosin 4 mg/day or metoprolol alone. The dose of metoprolol was gradually increased to a target dose of 50 mg orally twice daily. Hemodynamic measurements were obtained before drug therapy, 2 hours after the first dose of combined alpha-beta therapy or metoprolol alone, and after 3 months of continuous treatment. Nuclear ejection fraction, plasma norepinephrine, and submaximal and maximal exercise capacity were also measured before and after chronic therapy. With initial combined drug administration, mean arterial pressure, left ventricular filling pressure, and systemic vascular resistance decreased significantly compared with results after metoprolol alone. However, after 3 months of continuous therapy, both treatment groups showed similar and significant reductions in systemic vascular resistance and heart rate, with significant increases in cardiac index, stroke volume index, stroke work index, ejection fraction, and exercise capacity. Furthermore, the next dose of chronic combined medication no longer showed vasodilating effects. Chronic therapy with fixed-dose doxazosin and increasing doses of metoprolol produced identical effects as those seen in patients receiving metoprolol alone.
- Published
- 1996
- Full Text
- View/download PDF
21. Safety and efficacy of beta blockade in patients with chronic congestive heart failure awaiting transplantation.
- Author
-
Kalman J, Buchholz C, Steinmetz M, Courtney M, Gass A, Lansman S, and Kukin ML
- Subjects
- Adrenergic beta-Antagonists adverse effects, Adult, Angiotensin-Converting Enzyme Inhibitors administration & dosage, Angiotensin-Converting Enzyme Inhibitors adverse effects, Digoxin administration & dosage, Digoxin adverse effects, Diuretics administration & dosage, Diuretics adverse effects, Drug Therapy, Combination, Exercise Test drug effects, Female, Heart Failure physiopathology, Hemodynamics physiology, Humans, Long-Term Care, Male, Metoprolol adverse effects, Middle Aged, Palliative Care, Treatment Outcome, Ventricular Function, Left drug effects, Ventricular Function, Left physiology, Adrenergic beta-Antagonists administration & dosage, Heart Failure drug therapy, Heart Transplantation physiology, Hemodynamics drug effects, Metoprolol administration & dosage, Waiting Lists
- Abstract
Background: Donor availability remains a limiting factor for heart transplantation while transplant waiting time entails significant morbidity and mortality. This study was designed to assess the efficacy and safety of long-term beta blockade as optimization of therapy in patients with severe congestive heart failure already receiving digoxin, diuretics, and converting enzyme inhibitors awaiting transplantation., Methods: The beta-1 antagonist metoprolol was given to 19 patients with moderate to severe congestive heart failure. Hemodynamic, clinical, and neurohormonal measurements were obtained before drug therapy and after 3 months of treatment. Patients initially received 6.25 mg of metoprolol orally twice daily which was increased to a target dose of 50 mg twice daily over several weeks., Results: Metoprolol produced significant clinical, exercise, and hemodynamic benefits. Long-term therapy was associated with improvements in New York Heart Association class, ejection fraction, 6-minute walk, and peak maximal oxygen consumption. There were significant decreases in heart rate, pulmonary arterial systolic pressure, and left ventricular filling pressure with significant increases in stroke volume index and stroke work index. Four patients were removed from the transplant list after improving to New York Heart Association I. Only one patient required hospitalization during the first 6 months of therapy. There were no deaths caused by progressive heart failure; however, one patient died suddenly., Conclusions: Beta blockade with metoprolol can be safely administered to patients awaiting heart transplantation producing clinical, exercise, and hemodynamic improvements. Thus, beta blockade may prove to be a safe and cost-effective bridge to transplantation.
- Published
- 1995
22. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure.
- Author
-
Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, and Katz SD
- Subjects
- Adult, Aged, Carbazoles adverse effects, Carvedilol, Chronic Disease, Double-Blind Method, Female, Heart Failure physiopathology, Hemodynamics drug effects, Humans, Male, Middle Aged, Propanolamines adverse effects, Adrenergic beta-Antagonists therapeutic use, Carbazoles therapeutic use, Heart Failure drug therapy, Propanolamines therapeutic use, Vasodilator Agents therapeutic use
- Abstract
Background: Clinical trials have shown that beta-adrenergic blocking drugs are effective and well tolerated in patients with mild to moderate heart failure, but the utility and safety of these drugs in patients with advanced disease have not been evaluated., Methods and Results: We enrolled 56 patients with severe chronic heart failure into a double-blind, placebo-controlled study of the vasodilating beta-blocker carvedilol. All patients had advanced heart failure, as evidenced by a mean left ventricular ejection fraction of 0.16 +/- 0.01 and a mean maximal oxygen consumption of 13.6 +/- 0.6 mL.kg-1.min-1 despite digitalis, diuretics, and an angiotensin-converting enzyme inhibitor (if tolerated). After a 3-week, open-label, up-titration period, 49 of the 56 patients were assigned (in a double-blind fashion using a 2:1 randomization) to receive either carvedilol (25 mg BID, n = 33) or matching placebo (n = 16) for 14 weeks, while background therapy remained constant. Hemodynamic and functional variables were measured at the start and end of the study. Compared with the placebo group, patients in the carvedilol group showed improved cardiac performance, as reflected by an increase in left ventricular ejection fraction (P = .005) and stroke volume index (P = .010) and a decrease in pulmonary wedge pressure, mean right atrial pressure, and systemic vascular resistance (P = .003, .002, and .017, respectively). In addition, compared with placebo, patients treated with carvedilol benefited clinically, as shown by an improvement in symptom scores (P = .002), functional class (P = .013), and submaximal exercise tolerance (P = .006). The combined risk of death, worsening heart failure, and life-threatening ventricular tachyarrhythmia was lower in the carvedilol group than in the placebo group (P = .028), but carvedilol-treated patients had more dizziness and advanced heart block., Conclusions: Carvedilol produces clinical and hemodynamic improvement in patients who have severe heart failure despite treatment with angiotensin-converting enzyme inhibitors.
- Published
- 1995
- Full Text
- View/download PDF
23. Lymphocyte G proteins reflect response to treatment in congestive heart failure.
- Author
-
Horn EM, Kukin ML, Neuberg GW, Goldsmith RL, McCarty M, Gratch M, Medina N, Yushak M, Packer M, and Bilezikian JP
- Subjects
- Aged, Chronic Disease, Cyclic AMP blood, Female, GTP-Binding Proteins analysis, GTP-Binding Proteins drug effects, Heart Failure drug therapy, Heart Failure physiopathology, Hemodynamics drug effects, Humans, Lymphocytes chemistry, Lymphocytes drug effects, Male, Middle Aged, Norepinephrine blood, Radioligand Assay methods, Receptors, Adrenergic, beta analysis, Receptors, Adrenergic, beta drug effects, Receptors, Adrenergic, beta metabolism, Vasodilator Agents therapeutic use, GTP-Binding Proteins metabolism, Heart Failure blood, Lymphocytes metabolism
- Abstract
Congestive heart failure is associated with chronotropic and inotropic hyporesponsiveness to adrenergic stimulation. A decrease in Gs alpha or an increase in Gi alpha is associated with a decrease in adenylyl cyclase activity. The current study assessed G proteins in response to treatment with direct-acting vasodilators and correlated changes in lymphocyte beta-adrenergic receptor components with changes in hemodynamic variables. Twenty-three patients with severe chronic congestive heart failure (New York Heart Association functional classes III and IV) were studied. Patients were grouped as responders (n = 10) or nonresponders (n = 13) on the basis of clinical assessment of functional status from questionnaires. Therapy was associated with an increase in cardiac index, a decrease in mean arterial pressure, and a decrease in systemic vascular resistance in all patients. Left ventricular filling pressure significantly decreased in responders (26 +/- 2 mm to 13 +/- 3 mm, p < 0.05) but did not change significantly in nonresponders. Similarly, mean right atrial pressure significantly decreased in responders (11 +/- 2 mm Hg to 4 +/- 1 mm Hg, p < 0.05) but did not change in nonresponders. Plasma norepinephrine increased significantly only in nonresponders (679 +/- 100 pg/ml to 1233 +/- 201 pg/ml, p < 0.05). Whereas lymphocyte beta-adrenergic receptor density and Gs did not significantly change, Gi increased after treatment only in the nonresponder group (23 +/- 5 to 51 +/- 11 fmol/mg, p < 0.05). A poor response to direct-acting vasodilators can be distinguished by reactive increases in plasma norepinephrine and lymphocyte Gi in the absence of a decrease in either left- or right-sided filling pressures.
- Published
- 1995
- Full Text
- View/download PDF
24. Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors.
- Author
-
Gottlieb SS, Kukin ML, Penn J, Fisher ML, Cines M, Medina N, Yushak M, Taylor M, and Packer M
- Subjects
- Adult, Aged, Catheterization, Swan-Ganz, Digitalis Glycosides therapeutic use, Diuretics therapeutic use, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Heart Failure classification, Heart Failure physiopathology, Humans, Male, Middle Aged, Monitoring, Physiologic, Quinolines pharmacology, Severity of Illness Index, Thermodilution, Time Factors, Vasodilator Agents pharmacology, Ventricular Function, Left, Captopril therapeutic use, Heart Failure drug therapy, Hemodynamics drug effects, Quinolines therapeutic use, Vasodilator Agents therapeutic use
- Abstract
Objectives: We evaluated the short- and long-term effects of flosequinan in 47 patients with severe heart failure despite ongoing captopril treatment., Background: There have been no previous evaluations of the long-term hemodynamic effects of any direct-acting vasodilator in patients with heart failure receiving an angiotensin-converting enzyme inhibitor. Flosequinan is an arterial and venous vasodilator with actions similar to those of the hydralazine-isosorbide dinitrate combination., Methods: After baseline hemodynamic measurements using balloon-tipped pulmonary artery and radial arterial catheters, patients were randomized to receive 50, 100 or 150 mg of flosequinan daily. Hemodynamic variables were measured immediately before and after short-term flosequinan administration and after 8 weeks of therapy., Results: With short-term flosequinan administration, mean arterial, right atrial and left ventricular filling pressures decreased by 6.4 +/- 1.1, 3.8 +/- 0.5 and 7.3 +/- 0.7 mm Hg, respectively (all p < 0.001). Cardiac index increased by 0.5 +/- 0.1 liters/min per m2, systemic vascular resistance decreased by 616 +/- 105 dynes.s.cm-5 and heart rate increased by 4 +/- 1 beats/min (all p < 0.001). After 8 weeks of long-term flosequinan administration, the vasodilator effect of a dose of flosequinan persisted. Compared with pretreatment baseline values, mean arterial, right atrial and left ventricular filling pressures at the peak effect of flosequinan were decreased by 3.5 +/- 1.3, 2.8 +/- 0.7 and 5.1 +/- 1.3 mm Hg, respectively (all p < 0.01). Systemic vascular resistance had decreased by 585 +/- 95 dynes.s.cm-5, cardiac index had increased by 0.5 +/- 0.1 liters/min per m2 and heart rate had increased by 10 +/- 2 beats/min (all p < 0.001)., Conclusions: The arterial and venous vasodilator flosequinan exerts both short- and long-term sustained hemodynamic effects in patients with heart failure receiving angiotensin-converting enzyme inhibitors.
- Published
- 1993
- Full Text
- View/download PDF
25. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).
- Author
-
Massie BM, Berk MR, Brozena SC, Elkayam U, Plehn JF, Kukin ML, Packer M, Murphy BE, Neuberg GW, and Steingart RM
- Subjects
- Adult, Aged, Digoxin therapeutic use, Diuretics therapeutic use, Drug Therapy, Combination, Electrocardiography, Ambulatory, Exercise Test, Female, Humans, Male, Middle Aged, Quality of Life, Quinolines adverse effects, Vasodilator Agents therapeutic use, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Heart Failure drug therapy, Heart Failure physiopathology, Quinolines therapeutic use
- Abstract
Background: Angiotensin converting enzyme inhibitors, diuretics, and digoxin are each effective in treating congestive heart failure, but many patients remain symptom-limited on all three medications. This trial was designed to determine whether the addition of oral flosequinan, a new direct-acting arterial and venous vasodilator with possible dose-dependent positive inotropic effects, improves exercise tolerance and quality of life in such patients., Methods and Results: In a randomized, double-blind multicenter trial, 322 patients with predominantly New York Heart Association class II or III congestive heart failure and left ventricular ejection fractions of 35% or less, who were stabilized on a diuretic, angiotensin converting enzyme inhibitor, and digoxin, were treated with 100 mg flosequinan once daily, 75 mg flosequinan twice daily, or matching placebo. Efficacy was evaluated with serial measurements of treadmill exercise time, responses to the Minnesota Living With Heart Failure Questionnaire (LWHF), and clinical assessments during a baseline phase and a 16-week treatment period. After 16 weeks, 100 mg flosequinan once daily produced a significant increment in median exercise time (64 seconds at 16 weeks) compared with placebo (5 seconds), whereas the higher-dose flosequinan group did not show a statistically significant increase. Flosequinan (100 mg once daily) also improved the overall LWHF score significantly compared with placebo; both active therapies decreased the physical component, but 75 mg flosequinan twice daily was associated with a trend toward worsening of the emotional component. Most clinical assessments tended to improve on active therapy., Conclusions: These results indicate that additional symptomatic benefit can be attained by adding flosequinan to a therapeutic regimen already including a converting enzyme inhibitor. Because in the future most patients will fall into this category, flosequinan is a potential adjunctive agent in the management of severe congestive heart failure. However, because recent evidence indicates that the flosequinan dose studied in the present trial has an adverse effect on survival, the benefit-to-risk ratio must be assessed in individual patients.
- Published
- 1993
- Full Text
- View/download PDF
26. Vasodilator therapy and survival in chronic congestive heart failure.
- Author
-
Kukin ML
- Subjects
- Captopril therapeutic use, Heart Failure mortality, Humans, Hydralazine therapeutic use, Prospective Studies, Randomized Controlled Trials as Topic, Heart Failure drug therapy, Vasodilator Agents therapeutic use
- Published
- 1992
- Full Text
- View/download PDF
27. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
- Author
-
Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, and Kukin ML
- Subjects
- Aged, Cardiotonic Agents adverse effects, Chronic Disease, Double-Blind Method, Drug Evaluation, Female, Follow-Up Studies, Heart Failure drug therapy, Humans, Male, Middle Aged, Milrinone, Phosphodiesterase Inhibitors adverse effects, Prospective Studies, Pyridones adverse effects, Survival Rate, Cardiotonic Agents therapeutic use, Heart Failure mortality, Phosphodiesterase Inhibitors therapeutic use, Pyridones therapeutic use
- Abstract
Background: Milrinone, a phosphodiesterase inhibitor, enhances cardiac contractility by increasing intracellular levels of cyclic AMP, but the long-term effect of this type of positive inotropic agent on the survival of patients with chronic heart failure has not been determined., Methods: We randomly assigned 1,088 patients with severe chronic heart failure (New York Heart Association class III or IV) and advanced left ventricular dysfunction to double-blind treatment with (40 mg of oral milrinone daily (561 patients) or placebo (527 patients). In addition, all patients received conventional therapy with digoxin, diuretics, and a converting-enzyme inhibitor throughout the trial. The median period of follow-up was 6.1 months (range, 1 day to 20 months)., Results: As compared with placebo, milrinone therapy was associated with a 28 percent increase in mortality from all causes (95 percent confidence interval, 1 to 61 percent; P = 0.038) and a 34 percent increase in cardiovascular mortality (95 percent confidence interval, 6 to 69 percent; P = 0.016). The adverse effect of milrinone was greatest in patients with the most severe symptoms (New York Heart Association class IV), who had a 53 percent increase in mortality (95 percent confidence interval, 13 to 107 percent; P = 0.006). Milrinone did not have a beneficial effect on the survival of any subgroup. Patients treated with milrinone had more hospitalizations (44 vs. 39 percent, P = 0.041), were withdrawn from double-blind therapy more frequently (12.7 vs. 8.7 percent, P = 0.041), and had serious adverse cardiovascular reactions, including hypotension (P = 0.006) and syncope (P = 0.002), more often than the patients given placebo., Conclusions: Our findings indicate that despite its beneficial hemodynamic actions, long-term therapy with oral milrinone increases the morbidity and mortality of patients with severe chronic heart failure. The mechanism by which the drug exerts its deleterious effects is unknown.
- Published
- 1991
- Full Text
- View/download PDF
28. Management of patients with heart failure and angina: do coexistent diseases alter the response to cardiovascular drugs?
- Author
-
Packer M and Kukin ML
- Subjects
- Adrenergic beta-Antagonists therapeutic use, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Calcium Channel Blockers therapeutic use, Digitalis Glycosides therapeutic use, Drug Interactions, Humans, Angina Pectoris complications, Angina Pectoris drug therapy, Heart Failure complications, Heart Failure drug therapy
- Published
- 1991
- Full Text
- View/download PDF
29. The erythrocyte sedimentation rate in congestive heart failure.
- Author
-
Haber HL, Leavy JA, Kessler PD, Kukin ML, Gottlieb SS, and Packer M
- Subjects
- Female, Fibrinogen analysis, Follow-Up Studies, Heart Failure mortality, Heart Failure physiopathology, Hemodynamics, Humans, Male, Middle Aged, Blood Sedimentation, Heart Failure blood
- Abstract
Background and Methods: Physicians have long believed that the erythrocyte sedimentation rate is low in patients with congestive heart failure, but this concept is based on a misinterpretation of the results in a single report published in 1936. To reevaluate this concept in the modern era, we measured the sedimentation rate in 242 patients who were referred for treatment of chronic heart failure., Results: The sedimentation rate was low (less than 5 mm per hour) in only 24 patients (10 percent) but was increased (above 25 mm per hour) in 50 percent. Patients with low or normal sedimentation rates (less than or equal to 25 mm per hour) had more severe hemodynamic abnormalities than patients with elevated rates: lower cardiac index (mean +/- SEM, 1.7 +/- 0.1 vs. 2.0 +/- 0.1 liters per minute per square meter of body-surface area) and higher mean right atrial pressure (mean +/- SEM, 12 +/- 1 vs. 9 +/- 1 mm Hg) (both P less than 0.0001). New York Heart Association functional class IV symptoms were present in 66 percent of the patients with a low or normal sedimentation rate, as compared with 42 percent of those with elevated rates (P less than 0.0001). After one to three months of therapy, patients whose sedimentation rates decreased showed little hemodynamic or clinical response to treatment, whereas both cardiac performance and functional status improved in patients whose rates increased (P less than 0.02 for the comparison between groups). The sedimentation rate was correlated with the plasma fibrinogen level (r = 0.64, P = 0.0025), and changes in the sedimentation rate during treatment were correlated inversely with changes in mean right atrial pressure (r = -0.57, P = 0.0002). During long-term follow-up, patients with low or normal sedimentation rates had a worse one-year survival than patients with elevated rates (41 vs. 66 percent, P = 0.01)., Conclusions: These data indicate that the erythrocyte sedimentation rate is correlated with the severity of illness in patients with chronic heart failure. Because of its lack of discriminatory power, however, the test is of limited value in the clinical management of this disorder.
- Published
- 1991
- Full Text
- View/download PDF
30. Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure.
- Author
-
Neuberg GW, Kukin ML, Penn J, Medina N, Yushak M, and Packer M
- Subjects
- Adult, Aged, Aged, 80 and over, Humans, Male, Middle Aged, Dipeptides pharmacology, Heart Failure physiopathology, Hemodynamics drug effects, Renin antagonists & inhibitors, Renin-Angiotensin System drug effects
- Abstract
Previous efforts to block the renin-angiotensin system in patients with chronic congestive heart failure (CHF) have focused on 2 distal sites in the system, the angiotensin-converting enzyme and the angiotensin II receptor. Recent work, however, has led to the development of agents that directly inhibit renin, the proximal step in the cascade. In this study, we investigated the hemodynamic effects of renin inhibition in 9 patients with chronic CHF by using enalkiren, a primate-selective, dipeptide renin inhibitor, which has been previously shown to suppress plasma renin activity and to lower blood pressure in hypertensive patients. The acute intravenous administration of enalkiren (1.0 mg/kg) produced increases in cardiac index (2.0 +/- 0.3 to 2.3 +/- 0.1 liter/min/m2) and stroke volume index (26 +/- 3 to 34 +/- 4 ml/m2) and decreases in left ventricular filling pressure (31 +/- 3 to 25 +/- 3 mm Hg), mean right atrial pressure (15 +/- 1 to 13 +/- 2 mm Hg), heart rate (78 +/- 5 to 72 +/- 6 beats/min) and systemic vascular resistance (2,199 +/- 594 to 1,339 +/- 230 dynes.s.cm-5) (all p less than 0.01 to 0.05). These observations indicate that renin inhibition produces hemodynamic benefits in patients with chronic CHF and could potentially provide a novel approach to interfering with the renin-angiotensin system in patients with this disorder.
- Published
- 1991
- Full Text
- View/download PDF
31. Prognostic importance of the serum magnesium concentration in patients with congestive heart failure.
- Author
-
Gottlieb SS, Baruch L, Kukin ML, Bernstein JL, Fisher ML, and Packer M
- Subjects
- Female, Follow-Up Studies, Heart Failure mortality, Humans, Male, Middle Aged, Prevalence, Prognosis, Survival Analysis, Survival Rate, Time Factors, Heart Failure blood, Magnesium blood
- Abstract
Magnesium abnormalities are common in patients with congestive heart failure but the clinical and prognostic significance of an abnormal serum magnesium concentration in this disorder has not been investigated. Therefore, the relation between serum magnesium concentration and the clinical characteristics and long-term outcome of 199 patients with chronic heart failure was evaluated. The serum magnesium concentration was less than 1.6 mEq/liter in 38 patients (19%), within the normal range in 134 patients (67%) and greater than 2.1 mEq/liter in 27 patients (14%). Patients with hypomagnesemia had more frequent ventricular premature complexes and episodes of ventricular tachycardia than did patients with a normal serum magnesium concentration (p less than 0.05). Even though the two groups were similar with respect to severity of heart failure and neurohormonal variables, patients with a low serum magnesium concentration had a significantly worse prognosis during long-term follow-up (45% versus 71% 1 year survival, p less than 0.05). Patients with hypermagnesemia had more severe symptoms, greater neurohormonal activation and worse renal function than did patients with a normal serum magnesium concentration but tended to have fewer ventricular arrhythmias. Hypermagnesemic patients had a worse prognosis than did those with a normal magnesium concentration (37% versus 71% 1 year survival, p less than 0.05). In conclusion, the measurement of serum magnesium concentration provides important clinical and prognostic information in patients with chronic heart failure.
- Published
- 1990
- Full Text
- View/download PDF
32. Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure.
- Author
-
Gottlieb SS, Kukin ML, Medina N, Yushak M, and Packer M
- Subjects
- Aged, Clinical Trials as Topic, Encainide, Female, Humans, Lidocaine adverse effects, Male, Random Allocation, Tocainide, Anilides adverse effects, Anti-Arrhythmia Agents adverse effects, Heart Failure drug therapy, Hemodynamics drug effects, Lidocaine analogs & derivatives, Procainamide adverse effects
- Abstract
Many of the newer antiarrhythmic agents are said to cause minimal myocardial depression, but their hemodynamic effects have not been invasively evaluated and compared in patients with severe chronic heart failure. In a randomized, crossover study, the hemodynamic responses to single oral doses of procainamide (750 mg), tocainide (600 mg), and encainide (50 mg) given to 21 patients with severe chronic heart failure were compared. Cardiac performance decreased with all three drugs, but the magnitude of deterioration differed among the three agents. Stroke volume index decreased with procainamide (-5 +/- 1 ml/m2, p less than 0.001), tocainide (-7 +/- 1 ml/m2, p less than 0.001), and encainide (-8 +/- 1 ml/m2, p less than 0.001), but the decline was significantly greater with encainide than with procainamide (p less than 0.05). Similarly, left ventricular filling pressure increased with tocainide and encainide (+4 +/- 1 and +5 +/- 2 mm Hg, respectively; both p less than 0.05), but not with procainamide; the increase was significantly greater with tocainide and encainide than with procainamide (p less than 0.001). These deleterious hemodynamic effects were accompanied by worsening symptoms of heart failure in six patients with encainide and seven patients with tocainide but in only two patients with procainamide. Serum levels for all drugs were in the therapeutic range. In conclusion, although the three type I antiarrhythmic agents tested may all adversely affect left ventricular function in patients with heart failure, encainide and tocainide are more likely than procainamide to cause hemodynamic and clinical deterioration.
- Published
- 1990
- Full Text
- View/download PDF
33. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure.
- Author
-
Gottlieb SS, Kukin ML, Ahern D, and Packer M
- Subjects
- Adult, Aged, Aged, 80 and over, Electrocardiography, Female, Follow-Up Studies, Heart Failure mortality, Humans, Male, Middle Aged, Monitoring, Physiologic, Prognosis, Risk Factors, Stroke Volume, Time Factors, Atrial Natriuretic Factor blood, Heart Failure blood
- Abstract
Several circulating neurohormones have been shown to have prognostic significance in patients with chronic heart failure, but the relation between plasma levels of atrial natriuretic peptide and mortality in this disorder remains unknown. Plasma levels of immunoreactive atrial natriuretic peptide were measured in 102 patients in whom left ventricular ejection fraction, ventricular arrhythmias on ambulatory electrocardiographic recording and plasma levels of norepinephrine, renin activity, aldosterone and arginine vasopressin were also measured. Compared with patients with atrial natriuretic peptide concentrations below the median value of 125 pg/ml, patients with higher levels of the peptide had a higher plasma renin activity (8.9 +/- 1.8 versus 2.6 +/- 0.4 ng/ml per h) and plasma norepinephrine (858 +/- 116 versus 538 +/- 45 pg/ml), more frequent premature ventricular depolarizations (4,485 +/- 715 versus 2,004 +/- 495/day) and more advanced hemodynamic abnormalities (all p less than 0.05). During the subsequent 13 to 25 months of follow-up, patients with high levels of atrial natriuretic peptide had a significantly lower rate of survival than did those whose initial circulating peptide concentrations were normal or mildly increased (p = 0.01). These data indicate that, in patients with chronic heart failure, plasma atrial natriuretic peptide provides important prognostic information. This may relate to the ability of the hormone to reflect the interplay of several pathophysiologic factors that contribute to mortality in this disease.
- Published
- 1989
- Full Text
- View/download PDF
34. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure.
- Author
-
Packer M, Lee WH, Kessler PD, Gottlieb SS, Bernstein JL, and Kukin ML
- Subjects
- Adrenergic beta-Antagonists therapeutic use, Angiotensin-Converting Enzyme Inhibitors, Epinephrine blood, Heart Failure drug therapy, Humans, Renin blood, Heart Failure physiopathology, Neurosecretory Systems physiopathology
- Abstract
Support for the concept that neurohormonal mechanisms play an important role in determining the survival of patients with severe chronic heart failure is derived from two lines of evidence: circulating levels of neurohormones are markedly elevated in patients who have a poor long-term prognosis and the survival of high-risk patients may be favorably modified by treatment with specific neurohormonal antagonists. Plasma norepinephrine is a major prognostic factor in patients with severe chronic heart failure, the most markedly elevated levels being observed in patients with the most unfavorable long-term prognosis. Data from uncontrolled studies suggest that low-dose beta-blockade may improve the survival of patients with dilated cardiomyopathy. Similar trends were noted in the Beta-Blocker Heart Attack Trial, in which patients with congestive heart failure before or accompanying their acute myocardial infarction experienced a significant reduction in sudden death when treated with beta-blockers. In contrast, there appeared to be little selective benefit in patients without heart failure, who presumably had low circulating levels of catecholamines. Similarly, serum sodium concentration is a major prognostic factor in patients with severe chronic heart failure, the shortest survival being observed in patients with the most severe hyponatremia. The poor long-term outcome of hyponatremic patients appears to be related to the marked elevation of plasma renin activity in these individuals, since (in retrospective studies) hyponatremic patients appeared to fare significantly better when treated with converting-enzyme inhibitors than when treated with vasodilator drugs that did not interfere with angiotensin II formation. In contrast, there appeared to be no selective benefit of converting-enzyme inhibition on the survival of patients with a normal serum sodium concentration, in whom plasma renin activity was low. These data suggest that neurohormonal systems may exert a deleterious effect on the survival of some patients with severe chronic heart failure, which may be favorably modified by long-term treatment with specific neurohormonal antagonists.
- Published
- 1987
35. The current status of angiotensin converting enzyme inhibitors in the management of patients with chronic heart failure.
- Author
-
Packer M, Kukin ML, Neuberg GW, Pinsky DJ, Penn J, and Abittan MH
- Subjects
- Angiotensin-Converting Enzyme Inhibitors adverse effects, Chronic Disease, Heart Failure physiopathology, Hemodynamics drug effects, Humans, Hypotension chemically induced, Kidney drug effects, Kidney physiology, Potassium metabolism, Risk Factors, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Heart Failure drug therapy
- Abstract
Angiotensin converting enzyme (ACE) inhibitors are the only therapeutic agents used in the treatment of chronic heart failure that have been shown to both improve symptoms and prolong life. These agents produce long-term haemodynamic and clinical benefits in about 60-65% of patients. The only reliable means of determining which patients are most likely to respond favourably to treatment is by a therapeutic trial; the response cannot be predicted by demographic factors, pretreatment left ventricular function or plasma renin activity. In addition to their symptomatic benefits, ACE inhibitors reduce the mortality of patients with chronic heart failure, possibly by decreasing ventricular wall stress and decreasing the frequency and complexity of ventricular arrhythmias. The most serious adverse effects of treatment, hypotension, functional renal insufficiency and potassium retention, occur most commonly in patients with the most advanced disease [New York Heart Association (NYHA) class III and IV heart failure] and when efforts are made to block the formation of angiotensin (Ang) II continuously (as with the use of long-acting ACE inhibitors). The unique characteristics of the ACE inhibitors support their use as first-line agents in patients with chronic heart failure.
- Published
- 1989
36. Adverse hemodynamic and clinical effects of encainide in severe chronic heart failure.
- Author
-
Gottlieb SS, Kukin ML, Yushak M, Medina N, and Packer M
- Subjects
- Adult, Aged, Aged, 80 and over, Anilides blood, Anilides therapeutic use, Anti-Arrhythmia Agents blood, Anti-Arrhythmia Agents therapeutic use, Arrhythmias, Cardiac complications, Arrhythmias, Cardiac drug therapy, Dyspnea chemically induced, Encainide, Female, Heart Failure complications, Humans, Male, Middle Aged, Myocardial Contraction drug effects, Stroke Volume drug effects, Anilides adverse effects, Anti-Arrhythmia Agents adverse effects, Heart Failure physiopathology, Hemodynamics drug effects
- Abstract
Study Objective: To evaluate the hemodynamic effects of the antiarrhythmic drug, encainide, in patients with severe chronic heart failure., Design: Unblinded, before-after study., Setting: Referral center for patients with heart failure., Patients: Thirty patients with severe chronic heart failure and a left ventricular ejection fraction less than 40%., Interventions: Invasive hemodynamic measurements were done (using a balloon-tipped thermodilution catheter) before and for 3 hours after a single oral dose of 50 mg of encainide., Measurements and Main Results: Ninety to one hundred and twenty minutes after its administration, encainide produced a significant deterioration in cardiac performance, as reflected by a fall in cardiac index from 2.3 to 1.8 L/min.m2 body surface (mean change 0.5 +/- 0.1; P less than 0.001), a fall in stroke work index from 26 to 18 g.m/m2 (mean change 8 +/- 2; P less than 0.001), and an increase in left ventricular filling pressure from 19 to 22 mm Hg (mean change 3 +/- 2; P less than 0.05). These deleterious hemodynamic effects were accompanied by worsening symptoms of heart failure in 8 of the 30 patients. Serum levels of encainide and its metabolites, O-desmethylencainide and 3-methoxy-O-desmethylencainide, were within the therapeutic range in most patients., Conclusions: Encainide can cause adverse hemodynamic and clinical effects in patients with severe chronic heart failure.
- Published
- 1989
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.